Personal Resources Investment & Strategic Management Inc. Has $2.56 Million Holdings in Teva Pharmaceutical Industries (TEVA)

Personal Resources Investment & Strategic Management Inc. lowered its stake in Teva Pharmaceutical Industries (NYSE:TEVA) by 22.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,564 shares of the company’s stock after selling 38,947 shares during the period. Teva Pharmaceutical Industries comprises 1.5% of Personal Resources Investment & Strategic Management Inc.’s investment portfolio, making the stock its 10th biggest position. Personal Resources Investment & Strategic Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Teachers Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 66.5% during the 4th quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock worth $61,046,000 after acquiring an additional 1,286,637 shares in the last quarter. Millennium Management LLC raised its position in shares of Teva Pharmaceutical Industries by 56.6% during the 4th quarter. Millennium Management LLC now owns 2,965,936 shares of the company’s stock worth $56,204,000 after acquiring an additional 1,071,583 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its position in shares of Teva Pharmaceutical Industries by 1,498.9% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 328,228 shares of the company’s stock worth $6,220,000 after acquiring an additional 307,700 shares in the last quarter. Meitav Dash Investments Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $5,017,000. Finally, Synovus Financial Corp raised its position in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Synovus Financial Corp now owns 27,817 shares of the company’s stock worth $530,000 after acquiring an additional 6,029 shares in the last quarter. 58.18% of the stock is currently owned by institutional investors.

In other news, Director Roberto Mignone acquired 750,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, May 10th. The stock was purchased at an average cost of $19.24 per share, with a total value of $14,430,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 5,684 shares of company stock valued at $105,411. 0.43% of the stock is currently owned by insiders.

Several equities research analysts have recently weighed in on TEVA shares. ValuEngine lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $23.94 price target on the stock. in a research report on Monday, January 29th. Credit Suisse Group set a $23.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, April 4th. Mizuho reaffirmed a “buy” rating and set a $27.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday, April 20th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, January 23rd. Ten analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.82.

Shares of Teva Pharmaceutical Industries opened at $21.12 on Friday, Marketbeat reports. The firm has a market cap of $21.23 billion, a P/E ratio of 5.37, a PEG ratio of 1.71 and a beta of 0.67. Teva Pharmaceutical Industries has a 1 year low of $20.87 and a 1 year high of $21.36. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 3rd. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.28. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. Teva Pharmaceutical Industries’s revenue was down 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.06 earnings per share. research analysts predict that Teva Pharmaceutical Industries will post 2.45 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply